Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC
PaperCitations, authors & open-access status
A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 596 citations, 2018 year and bronze oa status.
596
Citations
2018
Year
bronze
OA Status